Lv5
1180 积分 2026-09-08 加入
Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas
6小时前
已完结
Pre-diagnostic clonal hematopoiesis of indeterminate potential among patients with a primary cancer and risk of second cancers
7小时前
已完结
Circulating Tumor DNA Testing in Solid Tumors and Lymphoma: ASCO Guideline
7小时前
已完结
Immune signature-based uncoupling of checkpoint inhibitor efficacy
11小时前
已完结
Sacubitril-Valsartan for the Prevention of Anthracycline Cardiotoxicity
11小时前
求助中
A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study
11小时前
已完结
Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy
11小时前
已完结
CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma
12小时前
已完结
ASTCT Consensus Grading for Toxicities after Immune Effector Cell Therapy
12小时前
已完结
Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High‐Age Patients (CRASH) score
12小时前
已完结
皖公网安备34019202002308
